In patients with NSCLC, alteration of KRAS/STK11 was found to have influence on tumor microenvironment and decrease PD-L1 expression levels, suggesting a lower response rate to ICIs and poorer prognosis 70,71. This evidence concerns the gene KRAS and non-small cell lung carcinoma.